XNCR Archived Articles
Xencor (XNCR): Navigating the Complexities of Biopharmaceutical Innovation
Published on March 13, 2025
Xencor (XNCR): Pioneering Engineered Antibodies for the Treatment of Cancer and Autoimmune Diseases
Published on November 30, 2024
Xencor, Inc. (NASDAQ:XNCR): Advancing a Robust Bispecific Pipeline with Promising Prostate Cancer Data
Published on September 24, 2024